EMA issues diabetes guidance

EMA's CHMP issued draft guidance on developing products to treat and prevent diabetes. The guidance says new glucose-lowering products should show a "neutral or beneficial effect " on cardiovascular risk. In contrast to guidelines from FDA, the EMA guidance does not indicate an acceptable point estimate for CV risk (see BioCentury, Dec. 15, 2008). ...